Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer | OncLive

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Kaklamani says it is known that women with breast and ovarian cancer who have BRCA1 or BRCA2 mutations can benefit from both carboplatin and PARP inhibitors, but it is unknown if women with breast and ovarian cancer who do not have these mutation also benefit from this therapy.

the

Using genetic testing, phase I/II study will try to identify which population of patients with breast and ovarian cancer will most benefit from the triple drug combination, Kaklamani says.


x